Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG

Core Insights - Kazia Therapeutics Limited is participating in a fully funded Australian Medical Research Future Fund project aimed at improving treatment for diffuse midline glioma (DMG) through an AI-enabled clinical decision-making platform [1][2][3] Project Overview - The initiative, named DMG-ADAPTS, will last three years and focus on optimizing the sequencing and timing of targeted therapies for DMG, which is a severe pediatric cancer with a median survival of less than one year [2][3] - DMG accounts for up to 25% of childhood brain cancer deaths, highlighting the urgent need for effective treatments [3] Kazia's Role - Kazia will provide its investigational drug paxalisib, a dual PI3K/mTOR inhibitor, which is currently being evaluated in multiple clinical studies for various brain cancers [4][5] - Positive signals have been reported in the PNOC 022 study, indicating encouraging activity of paxalisib in pediatric brain cancer [4] Strategic Importance - The project aims to integrate AI with precision therapies to potentially revolutionize the management of aggressive tumors like DMG and DIPG [5][7] - Kazia's involvement underscores its commitment to innovative solutions for pediatric cancers, leveraging global research excellence [5][6] Future Directions - The project will also focus on developing a cloud-based AI platform that integrates multiomics and profiling to guide individualized therapy decisions in real time [7] - Establishing non-invasive biomarkers to anticipate resistance and inform timely therapeutic transitions is a key goal of the initiative [7]